FDA Approves Zidesamtinib for Specific Type of Lung Cancer
Zidesamtinib (Jideytro) is approved for patients with ROS1-positive non-small cell lung cancer who have previously received targeted therapy.
Zidesamtinib (Jideytro) is approved for patients with ROS1-positive non-small cell lung cancer who have previously received targeted therapy.
Healthy lifestyle habits can repress the inflammatory effects of genetic mutations in white blood cells common in seniors.
UC San Diego Health successfully completed the first lung transplant for a patient with HIV in San Diego County.
Insmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP), being evaluated as a once-daily therapy for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders.
A clinical trial found that minimally invasive endovascular therapy reduces symptoms of post-thrombotic syndrome after deep vein thrombosis.
A patient with advanced lung cancer and interstitial lung disease received a double-lung transplant through a clinical trial at Northwestern Medicine.
Researchers have developed a new form of CRISPR technology that destroys harmful cells instead of editing their genes, while leaving healthy tissue untouched.